GTx reports positive results from toremifene Phase III clinical trial

Links shared publicly online about this topic.

1,109
total visits

GTx reports positive results from toremifene Phase III clinical trial

GTx, Inc. announced today that in the Phase III clinical trial evaluating toremifene 80 mg for the reduction of fractures and treatment of other estrogen deficiency side effects in men with prostate cancer on androgen deprivation therapy (ADT), toremifene treatment demonstrated an improved benefit/risk ratio in men less than 80 years of age. The data were presented yesterday at the 2010 Annual Meeting of the American Society of Clinical Oncology in Chicago.

View full resource at news-medical.net

Tags: Emergency, Fracture, Cancer, Prostate Cancer, Prostate, Clinical Trial, Men's Health, Estrogen

Most Recently Shared on June 8, 2010 at 6:36 pm By:

News-Medical.Net

Prostate Cancer: GTx reports positive results from toremifene Phase III clinical trial: GTx, Inc. announced today ... http://bit.ly/aY94OK

2 years ago...

Retweet

Favorite

GTx reports top line results from toremifene Phase III clinical trial for prostate cancer in men with high grade PIN

news-medical.net — “GTx, Inc. today announced top line results of the Phase III clinical trial evaluating toremifene 20 mg, a selective estrogen receptor modulator, for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia, or PIN, a premalignant lesion of the prostate.” View full resource at news-medical.net